Stop Chinese Fentanyl Act of 2025
Why China-relevant: To impose sanctions with respect to Chinese producers of synthetic opioids and opioid precursors, to hold Chinese officials accountable ... includes— (i) any entity of the People's Republic of China that the President determines ... produces, manufactures, distributes, sells, or knowingly finances or transports [opioid
Path to becoming law
- Introduced
- Passed committee
- Passed House
- Passed Senate next step
- Sent to President
- Became law
done next step still ahead
Legislative timeline — dated actions so far
- Filed
- Advanced in committee
- Advanced in committee
- Passed chamber (vote) [house]
3% to become law · 17% to clear committee
- + Broad cosponsorship (9 cosponsors)
- + Sponsored by a member of the majority party
- − Cosponsors are nearly all one party
Legislative likelihood — a tracking indicator, not investment advice.
Signals — secondary, directional
Directional context (see Methodology); the pinned, high-confidence axes are relevance and asset impact.
Shares that might be influenced
Each sector shows a direction (which way its China-related names are pushed) and, for precise mappings, how hard this bill hits the sector — rated marginal → very strong (1–5). Hover any chip for its definition. The headline 0–5 impact is at the top of the card.
domain 'fentanyl' -> pharma_china via stock_mapping.yaml (coarse fallback)
| Ticker | Name (Local) | Name (EN) | Restriction Lists |
|---|---|---|---|
| 688235.SS | 百济神州 | BEONE MEDICINES | |
| 600276.SS | 恒瑞医药 | HENGRUI PHARMA | |
| 603259.SS | 药明康德 | WuXi AppTec | |
| 3692.HK | 翰森制药 | Hansoh Pharmaceutical Group Company Limited | |
| 300760.SZ | 迈瑞医疗 | MR | |
| 2269.HK | 药明生物 | WUXI BIOLOGICS (CAYMAN) INC. | |
| 1801.HK | 信达生物 | Innovent Biologics, Inc. | |
| 6618.HK | 京东健康 | JD Health International Inc. | |
| 6990.HK | 科伦博泰生物 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | |
| 9926.HK | 康方生物 | Akeso,Inc. |